Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05387369
Recruiting Observational

A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19

NCT05387369 · tracked via the Priya Life Science China tracker
Sponsor
Huashan Hospital
Phase
Observational
Started
2022-03-21
Last updated
2022-05-24

Condition(s) studied

COVID-19

Investigational drug(s) / intervention(s)

Paxlovid →

Paxlovid: The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.

Study summary

The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.

Eligibility

Sex
ALL
Min age
12 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participants who have a positive SARS-CoV-2 test result; * Participants who have one or more mild or moderate COVID-19 symptoms. Exclusion Criteria: * No specific exclusion criteria in this real world study.

Primary outcome measure(s)

  • Viral shedding time — up to 28 days
    time from the first positive testing to the first day of nucleic acid Ct value\> 35 for both ORF1ab and N gene (in two consecutive).
  • Percentage of the participants who have progression of COVID-19 — up to 28 days
    Percentage of participants who experience these events by Day 28 Progress to severe and/or critical COVID-19; Death from any cause

Trial sites (1)

FacilityCityRegionStatus
Huashan Hospital Affiliated to Fudan University Shanghai China Recruiting

More Huashan Hospital trials in China

Real-World Study of Enarodustat for Anemia in Non-Dialysis CKD Patients Recruiting
Bilateral Single-Electrode VO Combined With STN-DBS for Treating Meige Syndrome Recruiting
The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function Recruiting
The Role of B7-H4 in Tumor Vaccine Recruiting
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China Recruiting

Other trials for the same condition

Corona Virus Disease 2019 Cohort Study Recruiting
Transcranial Ultrasound Stimulation for Cognitive Function Modulation in Patients With Post COVID-19 Brain Fog Recruiting
A Follow-up Study of Asymptomatic Infections and Diagnosed Patients With Covid-19 in Shanghai Recruiting
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study Recruiting
Smart Analysis and Decision-Making for Emerging Infectious Diseases Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05387369 on ClinicalTrials.gov ↗ ← All trials in China